- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05431153
A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants
November 8, 2022 updated by: Pfizer
A PHASE 1, RANDOMIZED, OPEN-LABEL, 4-PERIOD, 5-TREATMENT, 6-SEQUENCE, CROSSOVER, SINGLE-DOSE STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE EFFECT OF TABLET FORMULATION AND FOOD ON THE BIOAVAILABILITY OF PF-07104091
This is a single dose crossover pharmacokinetic (pharmacokinetics helps in understanding how the drug is changed and eliminated from the body after a participant takes it) study in healthy participants.
The study consists of 5 treatments, and each participant will be randomized to receive 4 of the treatments in separate periods in a specific sequence.
Each treatment consists of a single dose of PF-07104091 and the treatments differ by tablet formulation and/or whether the dose is to be given under fasted or fed conditions.
Plasma pharmacokinetics of PF-07104091 will be assessed following each dose to determine the effect of tablet formulation and fed condition on the relative bioavailability of PF-07104091.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
- Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
- Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
- Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
- Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- New Haven Clinical Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and standard 12 lead ECGs.
- Body-Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight of >50 kg (110 lb).
- Written evidence of a personally signed and dated informed consent document (ICD) indicating that the participant has been informed of all pertinent aspects of the study.
- Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
- History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAB) or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic (eg, contact with positive case, residence, or travel to an area with high incidence) that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
- A positive urine drug test.
- History of sensitivity to heparin or heparin induced thrombocytopenia.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PF-07104091 Sequence 1
Participants randomized to Sequence 1 will receive Treatments A, B, C, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
|
A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
Other Names:
|
Experimental: PF-07104091 Sequence 2
Participants randomized to Sequence 2 will receive Treatments B, C, A, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
|
A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
Other Names:
|
Experimental: PF-07104091 Sequence 3
Participants randomized to Sequence 3 will receive Treatments C, A, B, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
|
A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
Other Names:
|
Experimental: PF-07104091 Sequence 4
Participants randomized to Sequence 4 will receive Treatments A, B, C, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
|
A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
Other Names:
|
Experimental: PF-07104091 Sequence 5
Participants randomized to Sequence 5 will receive Treatments B, C, A, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
|
A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
Other Names:
|
Experimental: PF-07104091 Sequence 6
Participants randomized to Sequence 6 will receive Treatments C, A, B, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
|
A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
Other Names:
A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time(AUCinf) of PF-07104091 to estimate relative bioavailability of Tablet Formulations A, B, and C
Time Frame: 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
Maximum Observed Plasma Concentration (Cmax) of PF-07104091 to estimate relative bioavailability of Tablet Formulation A, B, and C
Time Frame: 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUCinf of PF-07104091 to estimate the effect of a high-fat, high-calorie meal on the bioavailability of Tablet Formulation C
Time Frame: 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Time Frame: From baseline up to 28 days after final dose of PF-07104091
|
From baseline up to 28 days after final dose of PF-07104091
|
Cmax of PF-07104091 to estimate the effect of a high-fat, high-calorie meal on the bioavailability of Tablet Formulation C
Time Frame: 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
AUCinf of PF-07104091 to estimate the bioavailability of Tablet Formulation D
Time Frame: 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
Cmax if PF-07104091 to estimate the bioavailability of Tablet Formulation D
Time Frame: 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
|
Participants With Laboratory Abnormalities
Time Frame: From baseline up to 28 days after final dose of PF-07104091
|
From baseline up to 28 days after final dose of PF-07104091
|
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings
Time Frame: From baseline up to 28 days after final dose of PF-07104091
|
From baseline up to 28 days after final dose of PF-07104091
|
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Time Frame: From baseline up to 28 days after final dose of PF-07104091
|
From baseline up to 28 days after final dose of PF-07104091
|
Number of Participants With Abnormalities in Physical Examination
Time Frame: From baseline up to 28 days after final dose of PF-07104091
|
From baseline up to 28 days after final dose of PF-07104091
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 10, 2022
Primary Completion (Actual)
October 17, 2022
Study Completion (Actual)
October 17, 2022
Study Registration Dates
First Submitted
June 9, 2022
First Submitted That Met QC Criteria
June 21, 2022
First Posted (Actual)
June 24, 2022
Study Record Updates
Last Update Posted (Actual)
November 9, 2022
Last Update Submitted That Met QC Criteria
November 8, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- C4161007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
-
PfizerRecruitingHealthy ParticipantsUnited States
-
AstraZenecaParexelCompletedCoronary Artery Disease (CAD)United Kingdom
-
SeqirusCompletedInfluenza, HumanUnited States
-
Agios Pharmaceuticals, Inc.Completed
-
Moon (Guangzhou) Biotechnology Co., Ltd.Not yet recruitingAdvanced Malignant Solid Tumors
-
AlyatecCompletedValidation of Strasbourg Environmental Exposure Chamber ALYATEC in Cat Allergic Subjects With AsthmaAllergy | Allergic Asthma | Allergy to CatsFrance
-
PfizerCompletedHypercholesterolemiaUnited States
-
Mereo BioPharmaNovartisCompleted
-
Laboratorios Silanes S.A. de C.V.Completed
-
Hangzhou Tangji Medical Technology Co., Ltd.Not yet recruiting